I would like to address the issue of what comparators we use. Various panellists have mentioned comparing to Australia or Scotland or comparing to Medicare in the United States. I would say that I definitely know comparing to Medicare in the United States is not an appropriate measure, since the majority of people are not covered by Medicare and Medicaid. In fact, they are covered more likely by UnitedHealthcare, and the UnitedHealthcare has a very different drug formulary than Medicare does. When we're comparing formularies, we need to look at what countries have the models we want, not just what is close or what highlights the disparities.
I think it is an issue of looking appropriately at what countries' values are and whether we share those values. That's the best way to look at how we should craft our drug review process.